Next 10 |
2024-05-02 08:49:35 ET More on Protara Therapeutics Protara: A Bombed Out Biotech With A Very Positive Skew Protara Therapeutics jumps 23% on $45M oversubscribed private financing Seeking Alpha’s Quant Rating on Protara Therapeutics Historical earnings...
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...
2024-04-22 10:01:12 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Tech advances are catalyzing the Health Care sector with improved ...
2024-04-05 09:17:42 ET More on Protara Therapeutics Protara: A Bombed Out Biotech With A Very Positive Skew Seeking Alpha’s Quant Rating on Protara Therapeutics Historical earnings data for Protara Therapeutics Financial information for Protara Therape...
2024-04-05 09:03:21 ET DENVER, Colo., Apr 05, 2024 ( 247marketnews.com )- Protara Therapeutics, Inc. (NASDAQ: TARA ) published three announcements today, including positive data from three-month evaluable carcinoma in situ (CIS) patients treated across its ongoing clinical prog...
NEW YORK, April 05, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that it has entered into a subscription agreement for the sale of an aggregate o...
New development pathway significantly expands addressable patient population for IV Choline Chloride IV Choline Chloride has the potential to become the first FDA-approved IV formulation of choline for the 40,000 PN patients in the U.S. Approximately 80% of PN patients are cho...
TARA-002 demonstrated a complete response rate of 43% at three months in BCG-Unresponsive /Experienced patients in ongoing NMIBC program TARA-002 demonstrated a complete response rate of 63% at three months in CIS-only patients in ongoing NMIBC program ...
2024-03-23 06:00:00 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you want to strike it rich via stocks to help you retire on a private island, the reality is this: You probably can’t go the buy-and-hold approach that legendary investors like Warren...
Preliminary results from ADVANCED-1EXP trial evaluating TARA-002 in NMIBC patients with CIS on track for 1H 2024 Preliminary data from ADVANCED-2 trial evaluating TARA-002 in NMIBC patients with BCG-unresponsive CIS and BCG-naïve CIS expected in 2H 2024 Cash, cash equivalen...
News, Short Squeeze, Breakout and More Instantly...
ArTara Therapeutics Inc. Company Name:
TARA Stock Symbol:
NASDAQ Market:
Reported positive data from three-month evaluable CIS patients treated across ongoing TARA-002 clinical program in NMIBC Preliminary data from six-month evaluable patients in ADVANCED-2 trial of TARA-002 in NMIBC expected in 2H 2024 Reached alignment with FDA on registrational p...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...
Friday, Protara Therapeutics Inc (NASDAQ:TARA) shared data from three-month evaluable carcinoma in situ (CIS) patients treated across TAR...